首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

2048868

恩普克斯疫苗和療法市場規模、佔有率和成長分析：按類型、通路和地區分類－2026-2033年產業預測

Monkeypox Vaccine And Treatment Market Size, Share, and Growth Analysis, By Type (Vaccines, Treatments), By Distribution (Government Stockpiling, Hospital Pharmacies), By Region - Industry Forecast 2026-2033

出版日期: 2026年05月20日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球恩普克斯疫苗和治療市場價值為 6.825 億美元，預計到 2025 年將成長至 7.4406 億美元，到 2033 年將成長至 14.854 億美元，在預測期（2026-2033 年）內複合年成長率為 9.02%。

受通用感染疾病蔓延的推動，恩波克斯疫苗和治療市場正轉型成為公共衛生領域的重要組成部分。該市場涵蓋多種產品，包括疫苗、抗病毒藥物、診斷工具以及用於預防和臨床應用的物流。其主要目標是迅速控制感染傳播，降低發病率，維護醫療衛生系統，並防止社會動盪。公眾意識的提高以及近期疫情的多方面爆發促使監管機構核准的藥品數量增加，從而吸引更多製造商進入該領域。各國政府和國際組織正在擴大採購規模，並專注於疫情監測和靈活的監管方式。這種轉變正在加速契約製造、低溫運輸物流和快速診斷的發展，並為許可和公平分銷創造機會，尤其是在資源匱乏的地區。

全球MPOX疫苗和治療市場促進因素

媒體通報的增加和監測力度的加強顯著提高了公眾對猴痘風險的認知，促使政策制定者和醫療衛生系統將疫苗和治療藥物的獲取放在首位。日益成長的緊迫性和對該疾病威脅的認知，正促使各國政府和國際組織投入資源，用於疫苗研發、儲備和供應策略。這種協調一致的應對措施表明，對疫苗生產商的需求不斷成長，迫使他們提高產能並加強供應鏈。公私合作正在簡化臨床開發流程，促進加強採購承諾的夥伴關係，並最終透過增加需求和降低疫苗及治療藥物供應商的商業性不確定性，推動市場成長。

全球猴痘疫苗和治療藥物市場面臨的限制因素

全球猴痘疫苗和治療藥物市場面臨許多限制因素，主要源自於疫苗生產和特殊治療藥物的嚴格要求。對高技能人才和符合嚴格生物安全標準的先進生產設施的需求，為新生產商設置了極高的進入門檻。這些挑戰導致供應瓶頸和產能擴張延遲，可能阻礙部分企業推動產品研發。此外，產能集中在少數現有供應商手中，增加了供應中斷的風險，削弱了市場競爭，從而限制了產品供應，阻礙了潛在新進入者的市場准入。

MPOX疫苗和治療市場的全球趨勢

全球猴痘疫苗和治療市場正經歷著向分散式供應鏈基礎設施的顯著轉變，旨在提升醫療服務體系的可及性和效率。這種模式強調建立社區診所和行動醫療團隊，從而能夠對局部疫情做出快速反應。此外，靈活的低溫運輸解決方案和數位化預約系統的整合，創造了高度靈活的醫療環境，並透過就近配送點增強了系統的可靠性。這些策略不僅改善了以患者為中心的醫療服務，還增強了供應鏈的韌性，並促進了國家計畫與地方醫療機構之間的合作，從而有效預防和治療猴痘。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Bavarian Nordic（JYNNEOS）
SIGA Technologies（TPOXX）
Chimerix（Brincidofovir）
Emergent BioSolutions
Pfizer Inc.
Johnson & Johnson
Merck & Co.
AstraZeneca
Takeda Pharmaceutical
Tonix Pharmaceuticals
Dynavax Technologies
Valneva SE
GeoVax Labs
iBio Inc.
Meridian Bioscience

結論與建議

簡介目錄

Product Code: SQMIG35I2628

Global Monkeypox Vaccine And Treatment Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 744.06 Million in 2025 to USD 1485.4 Million by 2033, growing at a CAGR of 9.02% during the forecast period (2026-2033).

The monkeypox vaccine and treatment market is driven by the increasing prevalence of zoonotic diseases, transforming it into a critical facet of public health. This market encompasses a range of products, including vaccines, antivirals, diagnostic tools, and logistics for prevention and clinical use. Its primary objective is to mitigate morbidity, maintain healthcare capacity, and swiftly contain outbreaks to prevent societal disruptions. Growing awareness and recent multipronged outbreaks have led to heightened regulatory approvals, encouraging more manufacturers to enter the space. National governments and international organizations have ramped up purchases, focusing on outbreak monitoring and flexible regulatory approaches. This shift promotes contract manufacturing, cold-chain logistics, rapid diagnostics, and opens opportunities for licensing and equitable distribution, particularly in resource-limited areas.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monkeypox Vaccine And Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monkeypox Vaccine And Treatment Market Segments Analysis

Global monkeypox vaccine and treatment market is segmented by type, distribution and region. Based on type, the market is segmented into Vaccines and Treatments. Based on distribution, the market is segmented into Government Stockpiling, Hospital Pharmacies and Public Health Programs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Monkeypox Vaccine And Treatment Market

Heightened media coverage and enhanced surveillance initiatives have significantly raised awareness about the risks tied to monkeypox, prompting policymakers and healthcare systems to prioritize the acquisition of vaccines and treatments. The growing urgency and perceived threat associated with the disease encourage governments and international organizations to dedicate resources toward research, stockpiling, and distribution strategies. This collective response indicates to manufacturers an increased demand, encouraging them to boost production capacities and enhance supply chains. Collaborative efforts between public and private sectors foster partnerships that streamline clinical development processes and reinforce procurement commitments, ultimately driving market growth through amplified demand and reduced commercial uncertainty for vaccine and treatment providers.

Restraints in the Global Monkeypox Vaccine And Treatment Market

The global monkeypox vaccine and treatment market faces significant restraints primarily due to the rigorous requirements for vaccine production and specialty therapeutics. The need for highly skilled personnel and advanced manufacturing facilities that adhere to strict biosafety standards creates substantial barriers to entry for new manufacturers. As a result, these challenges can lead to supply bottlenecks and prolong timelines for scaling production, ultimately preventing some companies from advancing their product development. Furthermore, the concentration of manufacturing capacity among a small number of established suppliers heightens the risks of supply disruptions and reduces competitive dynamics, culminating in limited product availability and restricted market access for potential new entrants.

Market Trends of the Global Monkeypox Vaccine And Treatment Market

The Global Monkeypox Vaccine and Treatment market is witnessing a significant trend towards decentralized delivery infrastructure, enhancing accessibility and efficiency in healthcare delivery systems. This approach emphasizes the establishment of community-based clinics and mobile units, enabling rapid responses to localized outbreaks. Furthermore, the integration of flexible cold-chain solutions and digital appointment scheduling is fostering an agile healthcare environment, enhancing trust in the system by utilizing familiar delivery points. These strategies not only improve patient-centered care but also strengthen the resilience of supply chains, facilitating better coordination between national programs and local providers for effective prevention and treatment of monkeypox.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Monkeypox Vaccine And Treatment Market Size by Type & CAGR (2026-2033)

Market Overview
Vaccines
- JYNNEOS (MVA-BN)
- ACAM2000
Treatments
- Tecovirimat (TPOXX)
- Cidofovir
- Brincidofovir

Global Monkeypox Vaccine And Treatment Market Size by Distribution & CAGR (2026-2033)

Market Overview
Government Stockpiling
Hospital Pharmacies
Public Health Programs

Global Monkeypox Vaccine And Treatment Market Size by Region & CAGR (2026-2033)

Market Overview
North America
Europe
Africa
Asia-Pacific

Global Monkeypox Vaccine And Treatment Market Size & CAGR (2026-2033)

North America (Type, Distribution, Region)
- US
- Canada
Europe (Type, Distribution, Region)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Distribution, Region)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Distribution, Region)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Distribution, Region)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bavarian Nordic (JYNNEOS)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SIGA Technologies (TPOXX)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chimerix (Brincidofovir)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tonix Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valneva SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeoVax Labs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iBio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments